Voyager Therapeutics (FRA:VT6) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VT6 Voyager Therapeutics Inc FRA:VT6
55 GF Score
Price €2.59
GF Value €1.38
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Voyager Therapeutics  (FRA:VT6) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Voyager Therapeutics Cyclically Adjusted PS Ratio Related Terms


Voyager Therapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Cyclically Adjusted PS Ratio Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 2.68 1.86

Voyager Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.47 2.20 1.86 1.81 0.00

FRA:VT6 vs NERV, DTIL, GLSI: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Voyager Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Cyclically Adjusted PS Ratio falls into.


FRA:VT6
55GF Score
Voyager Therapeutics Inc FRA:VT6
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Voyager Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Voyager Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.045/333.9520*333.9520
=0.045

Current CPI (Jun. 2026) = 333.9520.

Voyager Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.116 241.428 0.160
201612 0.088 241.432 0.122
201703 0.053 243.801 0.073
201706 0.040 244.955 0.055
201709 0.037 246.819 0.050
201712 0.183 246.524 0.248
201803 0.024 249.554 0.032
201806 0.069 251.989 0.091
201809 0.056 252.439 0.074
201812 0.055 251.233 0.073
201903 0.138 254.202 0.181
201906 1.075 256.143 1.402
201909 0.505 256.759 0.657
201912 0.798 256.974 1.037
202003 0.442 258.115 0.572
202006 0.688 257.797 0.891
202009 2.656 260.280 3.408
202012 0.144 260.474 0.185
202103 0.146 264.877 0.184
202106 0.030 271.696 0.037
202109 0.033 274.310 0.040
202112 0.657 278.802 0.787
202203 0.016 287.504 0.019
202206 0.018 296.311 0.020
202209 1.049 296.808 1.180
202212 -0.038 296.797 -0.043
202303 3.334 301.836 3.689
202306 0.103 305.109 0.113
202309 0.099 307.789 0.107
202312 1.637 306.746 1.782
202403 0.314 312.332 0.336
202406 0.476 314.175 0.506
202409 0.384 315.301 0.407
202412 0.103 315.605 0.109
202503 0.103 319.799 0.108
202506 0.077 322.561 0.080
202509 0.194 324.800 0.199
202512 0.222 324.054 0.229
202603 0.038 330.213 0.038
202606 0.045 333.952 0.045

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €2.59 is trading 87.5% above its estimated GF Value™ of €1.38. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €1.38 vs. price of €2.59 (87.5% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
55GF Score

Get the complete analysis for FRA:VT6

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.59
Price
€1.38
GF Value